228 related articles for article (PubMed ID: 24882271)
1. Inhaled liposomal amikacin.
Waters V; Ratjen F
Expert Rev Respir Med; 2014 Aug; 8(4):401-9. PubMed ID: 24882271
[TBL] [Abstract][Full Text] [Related]
2. Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections.
Antoniu S; Azoicai D
Drugs Today (Barc); 2013 Nov; 49(11):683-92. PubMed ID: 24308015
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
4. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
[TBL] [Abstract][Full Text] [Related]
5. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
7. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Antonela Antoniu S
Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
[TBL] [Abstract][Full Text] [Related]
8. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
9. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland.
Stelmach I; Korzeniewska A; Stelmach W
Respiration; 2008; 75(2):178-81. PubMed ID: 17435382
[TBL] [Abstract][Full Text] [Related]
10. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Lau WK; Young LS; Osher AB; Dooley RR
Pediatrics; 1977 Sep; 60(3):372-7. PubMed ID: 408787
[TBL] [Abstract][Full Text] [Related]
11. [Inhaled antibiotic therapy in cystic fibrosis].
Girón Moreno RM; Salcedo Posadas A; Mar Gómez-Punter R
Arch Bronconeumol; 2011 Jun; 47 Suppl 6():14-8. PubMed ID: 21703474
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
[TBL] [Abstract][Full Text] [Related]
13. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection.
Okusanya OO; Bhavnani SM; Hammel J; Minic P; Dupont LJ; Forrest A; Mulder GJ; Mackinson C; Ambrose PG; Gupta R
Antimicrob Agents Chemother; 2009 Sep; 53(9):3847-54. PubMed ID: 19451281
[TBL] [Abstract][Full Text] [Related]
15. Inhaled antibiotics for lower airway infections.
Quon BS; Goss CH; Ramsey BW
Ann Am Thorac Soc; 2014 Mar; 11(3):425-34. PubMed ID: 24673698
[TBL] [Abstract][Full Text] [Related]
16. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
[TBL] [Abstract][Full Text] [Related]
17. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.
Schaad UB; Wedgwood-Krucko J; Suter S; Kraemer R
J Pediatr; 1987 Oct; 111(4):599-605. PubMed ID: 3309236
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].
Rognon A; Curti C; Montana M; Terme T; Rathelot P; Vanelle P
Therapie; 2011; 66(6):481-91. PubMed ID: 22186073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
